Used in the treatment of hypercholesterolemia and other lipid disorders by inhibiting PCSK9, a protein that reduces the liver’s ability to remove low-density lipoprotein (LDL) cholesterol from the blood. By blocking PCSK9, this antibody increases the number of LDL receptors on liver cells, significantly lowering circulating LDL cholesterol levels. It is administered as a subcutaneous injection and is particularly effective in patients with familial hypercholesterolemia or those who cannot achieve target cholesterol levels with statins alone. Its high specificity and potency make it a valuable therapeutic option in cardiovascular disease prevention.